Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinjingping is a balanced electrolyte solution developed by Changsha Lixing Pharmaceutical Technology Development Co., Ltd. for intravenous administration. It is composed of six essential ionic components—sodium, potassium, magnesium, calcium, chloride, and acetate—formulated to closely resemble the electrolyte profile of human extracellular fluid. The solution is designed to treat hypovolemia and extracellular fluid depletion by providing rapid volume expansion and restoring electrolyte balance. Additionally, the inclusion of sodium acetate provides a buffering effect, as it is metabolized into bicarbonate in the body, making it effective for correcting metabolic acidosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on six elements electrolytes and sodium acetate injection.